Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if combining durvalumab with standard stereotactic
ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or
borderline resectable pancreatic cancer. The researchers will also look at the safety of the
combination treatment and any side effects it causes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cedars-Sinai Medical Center Memorial Sloan Kettering Cancer Center